The impact of high-risk cytogenetics on treatment efficacy and outcomes of patients with relapsed/refractory multiple myeloma: a systematic review and meta-analysis of randomized controlled trials

by | Jul 4, 2025 | Publications

Leukemia. 2025 Jul 2. doi: 10.1038/s41375-025-02677-5. Online ahead of print. ABSTRACT The cytogenetic abnormalities translocations t(4;14) and t(14;16) and the deletion of chromosome 17p in newly-diagnosed multiple myeloma are associated with poor disease prognosis...

Efficacy and safety of anti-CD38 monoclonal antibodies in patients with newly diagnosed multiple myeloma: an updated systematic review and meta-analysis based on randomized controlled trials

by | Jun 13, 2025 | Publications

Leuk Lymphoma. 2025 Jun 12:1-11. doi: 10.1080/10428194.2025.2512031. Online ahead of print. ABSTRACT THIS META-ANALYSIS OF EIGHT PHASE 3 RCTS ASSESSED EFFICACY AND SAFETY OF ANTI-CD38 MONOCLONAL ANTIBODIES (MABS) IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA...

Comparative Efficacy and Safety of Daratumumab-Integrated Quadruple Therapy Versus Triple Therapy in Transplant-Eligible Newly Diagnosed Multiple Myeloma: A Systematic Review and Meta-Analysis

by | Jun 6, 2025 | Publications

Clin Lymphoma Myeloma Leuk. 2025 May 14:S2152-2650(25)00159-4. doi: 10.1016/j.clml.2025.05.007. Online ahead of print. ABSTRACT BACKGROUND: The standard treatment for newly diagnosed, transplant-eligible multiple myeloma (NDMM) patients typically involves triplet...